


Cortisone

Cat. No.:	HY-17461												
CAS No.:	53-06-5												
Molecular Formula:	C ₂₁ H ₂₈ O ₅												
Molecular Weight:	360.44												
Target:	Glucocorticoid Receptor; Endogenous Metabolite												
Pathway:	Immunology/Inflammation; Vitamin D Related/Nuclear Receptor; Metabolic Enzyme/Protease												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>2 years</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 year</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	2 years		-20°C	1 year
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	2 years											
	-20°C	1 year											



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (277.44 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	2.7744 mL	13.8719 mL	27.7439 mL
		5 mM	0.5549 mL	2.7744 mL	5.5488 mL
10 mM		0.2774 mL	1.3872 mL	2.7744 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Cortisone (17-Hydroxy-11-dehydrocorticosterone), an oxidized metabolite of Cortisol (a Glucocorticoid). Cortisone acts as an immunosuppressant and anti-inflammatory agent. Cortisone can partially intervene in binding of Glucocorticoid to Glucocorticoid-receptor at high concentrations ^{[1][3][4]} .	
IC₅₀ & Target	Human Endogenous Metabolite	Human Endogenous Metabolite

In Vitro	<p>Cortisone (2.8-28,000 nM) dose-dependently attenuates the apoptosis induced by Cortisol in peripheral-blood mononuclear cells (PBMCs)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Cortisone (2 mg/kg; i.m. on alternate days for 2 months) decreases the BCG (the vaccine strain of tubercle bacillus) lesions and tuberculin reactions in rabbits^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male New Zealand white rabbits (2.1-2.4 kg) were injected with BCG at six days after the first administration^[2]</td> </tr> <tr> <td>Dosage:</td> <td>2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intramuscular injection on alternate days for 2 months</td> </tr> <tr> <td>Result:</td> <td> <p>Reduced the BCG lesions and tuberculin reactions.</p> <p>Reduced the number of infiltrating mononuclear cells (MN), the amount of caseous necrosis and ulceration, and the percent of NM that were beta-galactosidase-positive.</p> </td> </tr> </table>	Animal Model:	Male New Zealand white rabbits (2.1-2.4 kg) were injected with BCG at six days after the first administration ^[2]	Dosage:	2 mg/kg	Administration:	Intramuscular injection on alternate days for 2 months	Result:	<p>Reduced the BCG lesions and tuberculin reactions.</p> <p>Reduced the number of infiltrating mononuclear cells (MN), the amount of caseous necrosis and ulceration, and the percent of NM that were beta-galactosidase-positive.</p>
Animal Model:	Male New Zealand white rabbits (2.1-2.4 kg) were injected with BCG at six days after the first administration ^[2]								
Dosage:	2 mg/kg								
Administration:	Intramuscular injection on alternate days for 2 months								
Result:	<p>Reduced the BCG lesions and tuberculin reactions.</p> <p>Reduced the number of infiltrating mononuclear cells (MN), the amount of caseous necrosis and ulceration, and the percent of NM that were beta-galactosidase-positive.</p>								

CUSTOMER VALIDATION

- Drug Test Anal. 2020 Aug 27.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Hirano T, et, al. Cortisone counteracts apoptosis-inducing effect of cortisol in human peripheral-blood mononuclear cells. *Int Immunopharmacol*. 2001 Nov;1(12):2109-15.
- [2]. McCue RE, et, al. The effect of cortisone on the accumulation, activation, and necrosis of macrophages in tuberculous lesions. *Inflammation*. 1978 Jun;3(2):159-76.
- [3]. Seleem D, et, al. In Vivo Antifungal Activity of Monolaurin against *Candida albicans* Biofilms. *Biol Pharm Bull*. 2018;41(8):1299-1302.
- [4]. Rusu VM, et, al. In vivo effects of cortisone on the B cell line in chickens. *J Immunol*. 1975 Nov;115(5):1370-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA